

2021年第三季度报告

*Quarterly Financial Report
For the Third Quarter 2021*



甘李药业股份有限公司

Gan & Lee Pharmaceuticals.

(股票代码 Stock code : 603087.SH)

英文版仅为中文版之翻译，若中英歧义，请以中文版为准。

*The English translation is for reference purposes only.
In the event of any discrepancy between the Chinese original
and the English translation, the Chinese original shall prevail.*

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。

The Board of Directors and all directors of the Company assure that the contents of this notice is true, accurate and complete, and free from any false record, misleading representation or material omission, and undertake individual and joint legal liabilities.

重要内容提示

- 1. 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。
- 2. 公司负责人甘忠如、主管会计工作负责人孙程及会计机构负责人（会计主管人员）周丽保证季度报告中财务报表信息的真实、准确、完整。
- 3. 第三季度财务报表是否经审计

是 √ 否

Important Content Notes

- 1. The Board of Directors, the Supervisory Committee, directors, supervisors and senior management of Gan & Lee Pharmaceuticals. ('the Company') hereby assure that the content set out in the quarterly report is true, accurate and complete, and free from any false record, misleading representation or material omission, and undertake individual and joint legal liabilities.
- 2. Gan Zhongru (legal representative), Sun Cheng (Chief Accountant) and Zhou Li (Head of Accounting Department) hereby certify that the financial report set out in the annual report is true, accurate and complete.
- 3. Whether the third quarter financial statements are audited

Yes √ No

目 录

Contents

一、	主要财务数据	
I	Major Financial Data	04
二、	股东信息	
II	Shareholder information	08
三、	其他提醒事项	
III	Other reminders	10
四、	季度财务报表	
IV	Quarterly financial statements	11

一、主要财务数据

I Major financial data

(一) 主要会计数据和财务指标

(I) Major accounting data and financial indicators

单位：元 币种：人民币
In RMB

项目	Item	本报告期 The reporting period	本报告期比上年同期增减变动幅度 (%) Changes in the reporting period over the same period of the reporting period (%)	年初至报告期末 From the beginning of the year to the end of the reporting period	年初至报告期末比上年同期增减变动幅度 (%) From the beginning of the year to the end of the reporting period, changes over the same period of the reporting period (%)
营业收入	Operating income	1,027,645,195.77	4.40	2,503,074,955.69	14.21
归属于上市公司股东的净利润	Net profits attributable to shareholders of the listed company	498,640,867.59	31.72	871,410,498.42	26.99
归属于上市公司股东的扣除非经常性损益的净利润	Net profits attributable to shareholders of the listed company after deduction of non-recurring profits or losses	424,797,007.01	2.77	764,667,815.39	10.52
经营活动产生的现金流量净额	Net cash flow from Operating activities	不适用 Not applicable	不适用 Not applicable	781,580,179.90	-19.89
基本每股收益(元/股)	Basic earnings per share (RMB/share)	0.89	27.14	1.55	21.09
稀释每股收益(元/股)	Diluted earnings per share (RMB/share)	0.89	27.14	1.55	21.09
加权平均净资产收益率(%)	Weighted average return on net assets (%)	5.34	增加0.80个百分点 Increased by 0.80 percentage points	9.40	减少0.99个百分点 Decreased by 0.99 percentage points
		本报告期末 At the end of the reporting period	上年度末 At the end of the prior year	本报告期末比上年同期增减变动幅度(%) Changes at the end of the reporting period from the end of the prior year (%)	
总资产	Total assets	10,256,418,154.04	9,507,448,846.15	7.88	
归属于上市公司股东的所有者权益	Owners' equity attributable to shareholders of the listed company	9,583,347,354.96	8,938,520,381.40	7.21	

注：“本报告期”指本季度初至本季度末3个月期间，下同。

Note: “The reporting period” refers to the three-month period from the beginning of the quarter to the end of the quarter, the same below.

(二) 非经常性损益项目和金额

(II) Items and amounts of non-recurring profit or loss

单位：元 币种：人民币
In RMB

项目	Item	本报告期金额 Amount for the reporting period	年初至报告期末金额 Amount from the beginning of the year to the end of the reporting period
非流动性资产处置损益(包括已计提资产减值准备的冲销部分)	Profit or loss from disposal of non-current assets(including the write-off part of the provision for asset impairment)	-112,055.49	392,521.34
计入当期损益的政府补助(与公司正常经营业务密切相关,符合国家政策规定、按照一定标准定额或定量持续享受的政府补助除外)	Government grants recognized in profit or loss other than grants which are closely related to the Company's business and are either in fixed amounts or determined under quantitative methods in accordance with the national standard	3,611,716.92	40,584,431.86
除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资产、交易性金融负债产生的公允价值变动损益,以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益	Profit or loss on changes in the fair value of held-for-trading financial assets and held-for-trading financial liabilities, as well as the investment income on disposal of held-for-trading financial assets and held-for-trading financial liabilities, other than those used in the effective hedging activities relating to normal operating business	83,855,589.71	87,499,394.37
除上述各项之外的其他营业外收入和支出	Other non-operating income or expenses other than the above	-433,436.68	-3,567,032.17
其他符合非经常性损益定义的损益项目	Other losses and profits conforming to the definition of non-recurring profit and loss		622,734.43
减: 所得税影响额	Less: Amount affected by income tax	13,077,953.88	18,789,366.80
合计	Total	73,843,860.58	106,742,683.03

将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益项目的情况说明

☐ 适用 ☒ 不适用

Explanations on classifying any non-recurring gain or loss item mentioned in the <Explanatory Announcement No. 1 on Information Disclosure for Companies Offering Their Securities to the Public—Non-recurring Gains and Losses> as recurring gain or loss item.

☐ Applicable ☒ Not Applicable

(三) 主要会计数据、财务指标发生变动的情况、原因

(III) Changes in main accounting data and financial indicators and reasons

√适用 □不适用

√ Applicable □ Not Applicable

单位：元 币种：人民币
In RMB

项目名称	Item	变动比例(%) Change ratio (%)	主要原因 Main reason
交易性金融资产	Financial assets held for trading	52.88	主要系公司证券投资增加所致 Mainly due to the increase in company securities investment
应收款项融资	Financing receivables	16,876.33	主要系年初至报告期末采用银行承兑票据结算的销售收入增加且报告期末等待到期解付的银行承兑票据增加所致 Mainly due to the increase in sales income settled by bank acceptance bills from the beginning of the year to the end of the reporting period and the increase in bank acceptance bills yet to be settled at the end of the reporting period
预付款项	Prepayments	36.79	主要系预付原材料采购款增加所致 Mainly due to the increase in prepaid raw material purchases
一年内到期的非流动资产	Current portion of non-current assets	152.74	主要系一年内到期的大额存单增加所致 Mainly due to the increase in certificates of deposit maturing within one year
其他流动资产	Other current assets	-53.76	主要系收益凭证到期收回所致 Mainly due to the recovery of income certificates at maturity
债权投资	Debt investments	-57.09	主要系一年内到期的大额存单重分类至一年内到期的非流动资产所致 Mainly due to the reclassification of certificates of deposit due within one year to non-current assets due within one year
在建工程	Construction in progress	116.96	主要系年初至报告期末公司在建的山东项目持续投入所致 Mainly due to the continuous investment in the Company's Shandong project under construction from the beginning of the year to the end of the reporting period
使用权资产	Right-of-use assets	不适用 Not applicable	主要系采用新租赁准则，确认使用权资产所致 Mainly due to the adoption of the new lease standard to confirm the right-of-use assets;
递延所得税资产	Deferred tax assets	76.26	主要系年初至本报告期末对子公司可抵扣亏损、子公司收到政府补助款、交易性金融资产公允价值变动确认了递延所得税资产所致 Mainly due to the recognition of deferred tax assets on deductible losses of subsidiaries, government grants received by subsidiaries and changes in fair value of financial assets held for trading from the beginning of the year to the end of the reporting
其他非流动资产	Other non-current assets	103.22	主要系预付工程设备款和待抵扣进项税额增加所致 Mainly due to the increase in prepaid project equipment and input tax to be deducted
应付账款	Accounts payable	70.37	主要系应付原材料采购款、应付研发耗材款增加所致 Mainly due to the increase in payables for raw materials and R&D consumables
应交税费	Taxes payable	-44.05	主要系本报告期末应交所得税减少所致 Mainly due to the decrease in income tax payable at the end of the reporting period
其他应付款	Other payables	61.08	主要系应付工程设备款增加所致 Mainly due to the increase in payables for construction equipment
租赁负债	Lease liabilities	不适用 Not applicable	主要系采用新租赁准则，确认租赁负债所致 Mainly due to the adoption of the new lease standard to confirm the lease liability

单位：元 币种：人民币
In RMB

项目名称	Item	变动比例 (%) Change ratio (%)	主要原因 Main reason
营业成本_年初至报告期末	Operating costs_ from the beginning of the year to the end of the reporting	49.41	一方面系销售增长导致营业成本增加；另一方面系制剂类新品、医疗器械及原料药等毛利相对较低的产品本年销售大幅增长所致 On the one hand, sales growth led to an increase in operating costs; on the other hand, it was due to the substantial increase in sales of products with relatively low gross margins such as new preparations, medical devices and APIs
财务费用_年初至报告期末	Financial expenses_ from the beginning of the year to the end of the reporting	不适用 Not applicable	主要系年初至报告期末定期存款利息收入增加所致 Mainly due to the increase in interest income from time deposits from the beginning of the year to the end of the reporting
其他收益_年初至报告期末	Other income_ from the beginning of the year to the end of the reporting	192.64	主要系年初至报告期末计入其他收益的政府补助增加所致 Mainly due to the increase in government subsidies included in other income from the beginning of the year to the end of the reporting
投资收益_年初至报告期末	Investment income_ from the beginning of the year to the end of the reporting	194.76	主要系年初至报告期末证券收益增加所致 Mainly due to the increase in securities income from the beginning of the year to the end of the reporting
公允价值变动收益_年初至报告期末	Gain/(loss) on the changes in fair value_ from the beginning of the year to the end of the reporting	不适用 Not applicable	主要系公司持有的证券投资公允价值变动损失同比减少所致 Mainly due to the year-on-year decrease in fair value change losses on investments in securities held by the company
归属于上市公司股东的净利润_本报告期	Net profit attributable to shareholders of listed company_ during the reporting period	31.72	主要系本报告期营业收入增长、证券投资收益增加、持有的证券投资公允价值变动影响、研发费用加计扣除减少所得税费用所致 Mainly due to the increase in operating income, increase in income from securities investments, the impact of changes in fair value of securities investments held and the reduction in income tax expense due to the accrual of deductions for research and development expenses during the reporting period

二、股东信息

II Shareholder information

(一) 普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表

The total number of ordinary shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders

报告期末普通股股东总数 Total number of ordinary shareholders at the end of the reporting period		67,143	报告期末表决权恢复的优先股股东总数 (如有) Total number of preferred shareholders with voting rights restored at the end of the reporting period (if any)		无 Nil	
前10名股东持股情况 The shareholding of top ten shareholders						
股东名称 Shareholder name	股东性质 Nature of shareholders	持股数量 Number of shares held	持股比例(%) Shareholding ratio (%)	持有有限售条件股份数量 Number of restricted shares held	质押、标记或冻结情况 Description of pledge, marks or freeze	股份状态 If pledged or frozen
甘忠如 Gan Zhongru	境内自然人 Natural persons in China	177,135,207	31.54	177,135,207		无 Nil
明华创新技术投资(香港)有限公司 MING HUA TECHNOLOGY INVESTMENT (HK)LIMITED	境外法人 Overseas corporation	89,114,792	15.87	15,875,800		无 Nil
北京旭特宏达科技有限公司 Beijing Xute Hongda Technology Co., Ltd.	境内非国有法人 Non-state-owned corporation in China	47,494,437	8.46	47,494,437		无 Nil
Vast Wintersweet Limited	境外法人 Overseas corporation	34,056,996	6.06	5,777,913		无 Nil
STRONG LINK INTERNATIONAL LIMITED	国有法人 State-owned corporation in China	25,168,737	4.48	4,256,033		无 Nil
GS Direct,L.L.C.	境外法人 Overseas corporation	23,285,889	4.15	3,937,644		无 Nil
Hillhouse G&L Holdings(HK) Limited	境外法人 Overseas corporation	15,588,132	2.78	4,296,032		无 Nil
北京宽街博华投资中心(有限合伙) Beijing Kuanjie Bohua Investment Center (Limited Partnership)	其他 Other	14,012,741	2.50	2,781,922		无 Nil
天津启明创智股权投资基金合伙企业(有限合伙) Tianjin Qiming Chuangzhi Equity Investment Fund Partnership (Limited Partnership)	其他 Other	6,773,318	1.21	1,661,487		无 Nil
甘喜茹 Gan Xiru	境内自然人 Natural persons in China	6,223,276	1.11	6,223,276		无 Nil

单位：股
In Share

单位：股 In Share	前10名无限售条件股东持股情况 The shareholding of top ten shareholders of non-restricted shares				股份种类及数量 Category and number of shares	
	股东名称 Shareholder name	持有无限售条件流通股的数量 Number of unrestricted circulating shares	股份种类 Category	数量 Number		
	明华创新投资(香港)有限公司	MING HUA TECHNOLOGY INVESTMENT (HK)LIMITED	人民币普通股 RMB ordinary shares	73,238,992		
	Vast Wintersweet Limited	Vast Wintersweet Limited	人民币普通股 RMB ordinary shares	28,279,083		
	STRONG LINK INTERNATIONAL LIMITED	STRONG LINK INTERNATIONAL LIMITED	人民币普通股 RMB ordinary shares	20,912,704		
	GS Direct,L.L.C.	GS Direct,L.L.C.	人民币普通股 RMB ordinary shares	19,348,245		
	Hillhouse G&L Holdings (HK) Limited	Hillhouse G&L Holdings (HK) Limited	人民币普通股 RMB ordinary shares	11,292,100		
	北京宽街博华投资中心(有限合伙)	Beijing Kuanjie Bohua Investment Center (Limited Partnership)	人民币普通股 RMB ordinary shares	11,230,819		
	北京弘达兴盛科技有限公司	Beijing Hongda Xingsheng Technology Co., Ltd.	人民币普通股 RMB ordinary shares	5,161,873		
	天津启明创智股权投资基金合伙企业(有限合伙)	Tianjin Qiming Chuangzhi Equity Investment Fund Partnership (Limited Partnership)	人民币普通股 RMB ordinary shares	5,111,831		
	苏州启明创智股权投资合伙企业(有限合伙)	Suzhou Qiming Chuangzhi Equity Investment Partnership(limited Partnership)	人民币普通股 RMB ordinary shares	3,363,205		
	北京启明创科创业投资中心(有限合伙)	Beijing Qiming Chuangke Venture Capital Investment Center(L.P)	人民币普通股 RMB ordinary shares	2,623,329		

上述股东关联关系或一致行动的说明	
Explanation for related-party relationship or concerted actions among aforementioned shareholders	
公司控股股东、实际控制人甘忠如持有旭特宏达65.02%的股权；甘喜茹为甘忠如胞妹；GS Direct与宽街博华的实际控制人均为The Goldman Sachs Group, Inc (高盛集团)；天津启明的执行事务合伙人委派代表为邝子平，明华创新追溯至最终普通合伙人为Qiming Corporate GP II, Ltd.，其自然人股东之一为邝子平。除以上情况外，其他股东之间不存在关联关系或一致行动。	The company's controlling shareholder and actual controller Gan Zhongru holds 65.02% of the shares of Xute Hongda; Gan Xiru is Gan Zhongru's sister; GS Direct and Kuanjie Bohua's actual controller is The Goldman Sachs Group, Inc; Tianjin Qiming's executive affairs partner appointed Kuang Ziping as a representative, and MING HUA TECHNOLOGY traced back to the final general partner as Qiming Corporate GP II, Ltd., a natural person. One of the shareholders is Kuang Ziping. Except for the above circumstances, there is no associated relationship or concerted action among other shareholders.

三、其他提醒事项

III

Other reminders

需提醒投资者关注的关于公司报告期经营情况的其他重要信息

Other important information about the company's operating conditions during the reporting period that need to be reminded of investors

☐ 适用 ☒ 不适用

☐ Applicable ☒ Not Applicable

四、季度财务报表

IV Quarterly financial statements

(一) 审计意见类型

(I) Audit opinion type

☐ 适用 ☒ 不适用☐ Applicable ☒ Not Applicable

(二) 财务报表

(II) Financial statements

合并资产负债表

Consolidated Balance Sheet

2021年9月30日
September 30, 2021编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计
In RMB, Unaudited

项目	Item	2021年9月30日 September 30, 2021	2020年12月31日 December 31, 2020
流动资产:	Current Assets:		
货币资金	Cash and Cash equivalents	3,100,284,003.25	2,824,811,610.48
交易性金融资产	Held-for-trading financial assets	1,203,255,839.15	787,050,475.77
应收账款	Accounts receivable	673,169,951.63	827,076,539.93
应收款项融资	Financing receivables	45,625,594.17	268,760.00
预付款项	Prepayments	96,081,178.14	70,242,083.92
其他应收款	Other receivables	8,016,190.04	5,001,469.72
存货	Inventories	575,547,872.80	493,481,641.77
一年内到期的非流动资产	Current portion of non-current assets	273,822,835.62	108,341,438.36
其他流动资产	Other current assets	389,955,382.70	843,339,501.94
流动资产合计	Total current Assets	6,365,758,847.50	5,959,613,521.89
非流动资产:	Non-current Assets:		
债权投资	Debt investments	200,000,000.00	466,047,945.21
固定资产	Fixed assets	1,676,495,473.94	1,738,877,768.05
在建工程	Construction in progress	889,791,956.51	410,124,488.85
使用权资产	Use right assets	12,737,435.47	
无形资产	Intangible assets	266,022,404.87	238,917,726.54
开发支出	Development expenditures	533,213,536.07	530,704,797.92
长期待摊费用	Long-term prepaid expenses	12,427,818.03	13,570,027.42
递延所得税资产	Deferred tax assets	26,311,101.85	14,927,523.58
其他非流动资产	Other non-current assets	273,659,579.80	134,665,046.69
非流动资产合计	Total non-current Assets	3,890,659,306.54	3,547,835,324.26
资产总计	Total assets	10,256,418,154.04	9,507,448,846.15

合并资产负债表 (续)

Consolidated Balance Sheet (Continued)

项目	Item	2021年9月30日 September 30, 2021	2020年12月31日 December 31, 2020
流动负债：	Current Liabilities		
应付账款	Accounts payable	30,350,078.37	17,813,897.58
合同负债	Contract liabilities	52,842,178.77	68,442,734.65
应付职工薪酬	Payroll and employee benefits payable	124,772,846.68	105,502,987.37
应交税费	Taxes payable	37,342,676.30	66,741,390.93
其他应付款	Other payables	227,623,661.28	141,312,224.65
一年内到期的非流动负债	Current portion of non-current liabilities	3,657,629.47	9,087,839.22
其他流动负债	Other current liabilities	324,751.88	949,097.54
流动负债合计	Total Current Liabilities	476,913,822.75	409,850,171.94
非流动负债：	Non-current Liabilities:		
租赁负债	Leasing liabilities	13,761,007.45	
长期应付款	Long-term payable	1,030,663.74	1,690,159.92
递延收益	Deferred income	143,455,737.19	125,769,330.10
递延所得税负债	Deferred tax liabilities	38,072,067.53	31,781,078.01
非流动负债合计	Total Non-current Liabilities	196,319,475.91	159,240,568.03
负债合计	Total Liabilities	673,233,298.66	569,090,739.97
所有者权益(或股东权益)：	Owners' (or Shareholders') Equity:		
实收资本(或股本)	Paid-in capital (or share capital)	561,540,000.00	561,540,000.00
资本公积	Capital reserve	2,473,623,419.43	2,473,623,419.43
其他综合收益	Other comprehensive income	-3,518,512.44	-1,550,987.58
盈余公积	Surplus reserve	291,531,843.96	291,531,843.96
未分配利润	Retained earnings	6,260,170,604.01	5,613,376,105.59
归属于母公司所有者权益(或股东权益)合计	Equity attributable to owners of the parent	9,583,347,354.96	8,938,520,381.40
少数股东权益	Non-controlling interests	-162,499.58	-162,275.22
所有者权益(或股东权益)合计	Total Owners' (or Shareholders') Equity	9,583,184,855.38	8,938,358,106.18
负债和所有者权益(或股东权益)总计	Total Liabilities and Owners'(or Shareholders') Equity	10,256,418,154.04	9,507,448,846.15

公司负责人：甘忠如

主管会计工作负责人：孙程

会计机构负责人：周丽

Legal Representative : Gan Zhongru

Chief Accountant: Sun Cheng

Head of Accounting Department:

Zhou Li

合并利润表

Consolidated Income Statement

2021年1-9月

For the period from January 1, 2021 to September 30, 2021

编制单位:甘李药业股份有限公司

Prepared by: Gan & Lee Pharmaceuticals.

单位:元 币种:人民币 审计类型:未经审计

In RMB, Unaudited

项目	Item	2021年前三季度(1-9月) The first three quarters of 2021 (January to September)	2020年前三季度(1-9月) The first three quarters of 2020 (January to September)
一、营业总收入	I. Total Operating Revenue	2,503,074,955.69	2,191,734,700.32
其中:营业收入	Including: Operating revenue	2,503,074,955.69	2,191,734,700.32
二、营业总成本	II. Total Operating Costs	1,605,262,792.61	1,349,357,763.59
其中:营业成本	Including: Operating costs	284,918,023.43	190,696,729.34
税金及附加	Taxes and surcharges	18,653,003.61	16,792,518.06
销售费用	Selling expenses	730,407,295.30	654,481,929.41
管理费用	General and administrative expenses	237,866,109.00	205,724,873.42
研发费用	R&D expenses	350,755,199.82	284,763,250.29
财务费用	Financial expenses	-17,336,838.55	-3,101,536.93
加:其他收益	Add: other income	41,207,166.29	14,081,113.48
投资收益(损失以“—”号填列)	Investment/(loss) income (loss is indicated with “-”)	96,000,846.26	32,568,606.47
公允价值变动收益(损失以“—”号填列)	Gain/(loss) on the changes in fair value (loss is indicated with “-”)	-8,501,451.89	-49,896,253.12
信用减值损失(损失以“—”号填列)	Credit impairment losses (loss is indicated with “-”)	-2,383,787.12	4,938,163.51
资产处置收益(损失以“—”号填列)	Gain/(loss) from disposal of assets (loss is indicated with “-”)	392,521.34	-2,348,425.07
三、营业利润(亏损以“—”号填列)	III. Operating profit (loss is indicated with “-”)	1,024,527,457.96	841,720,142.00
加:营业外收入	Add: Non-operating income	223,364.72	335,412.52
减:营业外支出	Less: Non-operating expenses	3,790,396.89	1,042,155.70
四、利润总额(亏损总额以“—”号填列)	IV. Profit/(loss) before tax (total losses are indicated with “-”)	1,020,960,425.79	841,013,398.82
减:所得税费用	Less: Income tax expense	149,550,151.73	154,808,602.12
五、净利润(净亏损以“—”号填列)	V. Net profits (net losses are indicated with “-”)	871,410,274.06	686,204,796.70
(一)按经营持续性分类	(I) Categorized by operation continuity		
1.持续经营净利润(净亏损以“—”号填列)	1. Net profit from continuing operations (net losses are indicated with “-”)	871,410,274.06	686,204,796.70

合并利润表 (续)

Consolidated Income Statement (Continued)

项目	Item	2021年前三季度(1-9月) The first three quarters of 2021 (January to September)	2020年前三季度(1-9月) The first three quarters of 2020 (January to September)
(二) 按所有权归属分类	(II) Categorized by ownership		
1. 归属于母公司股东的净利润(净亏损以“-”号填列)	1. Net profit attributable to owners of the parent (net losses are indicated with "-")	871,410,498.42	686,204,873.53
2. 少数股东损益(净亏损以“-”号填列)	2. Net profit attributable to non-controlling interests (net losses are indicated with "-")	-224.36	-76.83
六、其他综合收益的税后净额	VI. Other comprehensive income, net of tax	-1,967,866.35	-1,335,513.66
(一) 归属母公司所有者的其他综合收益的税后净额	(I) Other comprehensive income, net of tax, attributable to owners of the parent	-1,967,866.35	-1,335,513.66
1. 不能重分类进损益的其他综合收益	1. Other comprehensive income will not be reclassified to profit or loss		
2. 将重分类进损益的其他综合收益	2. Other comprehensive income to be reclassified to profit or loss	-1,967,866.35	-1,335,513.66
(1) 外币财务报表折算差额	(1) Exchange differences on translation of foreign currency financial statements	-1,967,866.35	-1,335,513.66
七、综合收益总额	VII. Total comprehensive income	869,442,407.71	684,869,283.04
(一) 归属于母公司所有者的综合收益总额	(I) Total comprehensive income attributable to owners of the parent	869,442,632.07	684,869,359.87
(二) 归属于少数股东的综合收益总额	(II) Total comprehensive income attributable to non-controlling interests	-224.36	-76.83
八、每股收益：	VIII. Earnings per share:		
(一) 基本每股收益(元/股)	(I) Basic earnings per share (yuan/share)	1.55	1.28
(二) 稀释每股收益(元/股)	(II) Diluted earnings per share (yuan/share)	1.55	1.28

本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0元，上期被合并方实现的净利润为：0元。

For business combination involving entities under common control occurred during the period, net profit of the acquiree generated before the business combination is nil, and net profit of the acquiree generated in prior period is nil.

公司负责人：甘忠如

主管会计工作负责人：孙程

会计机构负责人：周丽

Legal Representative: Gan Zhongru

Chief Accountant: Sun Cheng

Head of Accounting Department:

Zhou Li

合并现金流量表

Consolidated Cash Flows Statement

2021年1-9月

For the period from January 1, 2021 to September 30, 2021

编制单位:甘李药业股份有限公司

Prepared by: Gan & Lee Pharmaceuticals.

单位:元 币种:人民币 审计类型:未经审计

In RMB, Unaudited

项目	Item	2021年前三季度(1-9月) The first three quarters of 2021 (January to September)	2020年前三季度(1-9月) The first three quarters of 2020 (January to September)
一、经营活动产生的现金流量:	I. Cash Flows from Operating Activities:		
销售商品、提供劳务收到的现金	Cash receipts from the sale of goods and the rendering of services	2,585,392,743.85	2,484,324,807.47
收到的税费返还	Tax refunds received	4,991,037.83	588,789.78
收到其他与经营活动有关的现金	Cash received relating to other operating activities	64,045,043.11	52,962,147.26
经营活动现金流入小计	Sub-total of cash inflows from operating activities	2,654,428,824.79	2,537,875,744.51
购买商品、接受劳务支付的现金	Cash paid for purchase of goods and services	383,987,995.89	254,936,381.93
支付给职工及为职工支付的现金	Cash paid to and on behalf of employee	454,002,985.83	359,655,448.33
支付的各项税费	Cash paid for taxes	282,371,412.54	320,064,647.32
支付其他与经营活动有关的现金	Cash paid relating to other operating activities	752,486,250.63	627,526,542.20
经营活动现金流出小计	Sub-total of cash outflows from operating activities	1,872,848,644.89	1,562,183,019.78
经营活动产生的现金流量净额	Net cash flow from operating activities	781,580,179.90	975,692,724.73
二、投资活动产生的现金流量:	II. Cash Flows from Investing Activities:		
收回投资收到的现金	Cash received from disposal of investments	1,590,000,000.00	4,798,100,000.00
取得投资收益收到的现金	Cash receipts from investment income	59,243,983.36	44,003,931.75
处置固定资产、无形资产和其他长期资产收回的现金净额	Net proceeds from disposal of property, plant and equipment, intangible assets and other long-term assets	690,389.38	825,000.00
投资活动现金流入小计	Sub-total of cash inflows from investing activities	1,649,934,372.74	4,842,928,931.75
购建固定资产、无形资产和其他长期资产支付的现金	Purchase of property, plant and equipment, intangible assets and other non-current assets	538,540,556.62	393,905,753.30
投资支付的现金	Cash paid for investments	1,089,999,999.84	7,277,100,000.00
支付其他与投资活动有关的现金	Cash paid relating to other investing activities	391,360,000.00	399,873,110.16
投资活动现金流出小计	Sub-total of cash outflows from investing activities	2,019,900,556.46	8,070,878,863.46
投资活动产生的现金流量净额	Net cash flow from investing activities	-369,966,183.72	-3,227,949,931.71

合并现金流量表 (续)

Consolidated Cash Flows Statement (Continued)

项目	Item	2021年前三季度 (1-9月) The first three quarters of 2021 (January to September)	2020年前三季度 (1-9月) The first three quarters of 2020 (January to September)
三、筹资活动产生的现金流量：	III. Cash Flows from Financing Activities:		
吸收投资收到的现金	Cash received from investments		2,441,134,463.77
筹资活动现金流入小计	Subtotal of cash inflows from financing activities		2,441,134,463.77
分配股利、利润或偿付利息支付的现金	Cash payments for distribution of dividends or profit and interest expenses	224,616,000.00	141,418,450.67
支付其他与筹资活动有关的现金	Cash payments relating to other financing activities	2,559,464.33	
筹资活动现金流出小计	Sub-total of cash outflows from financing activities	227,175,464.33	141,418,450.67
筹资活动产生的现金流量净额	Net cash flow from financing activities	-227,175,464.33	2,299,716,013.10
四、汇率变动对现金及现金等价物的影响	IV. Effect of exchange rate changes on cash and cash equivalents	13,736,922.87	-957,080.79
五、现金及现金等价物净增加额	V. Net Increase in Cash and Cash Equivalents	198,175,454.72	46,501,725.33
加：期初现金及现金等价物余额	Add: Cash and cash equivalents at beginning of year	291,335,227.78	33,217,208.47
六、期末现金及现金等价物余额	VI. Cash and cash equivalents at end of year	489,510,682.50	79,718,933.80

公司负责人：甘忠如

主管会计工作负责人：孙程

会计机构负责人：周丽

Legal Representative : Gan Zhongru

Chief Accountant: Sun Cheng

Head of Accounting Department: Zhou Li

(三) 2021年起首次执行新租赁准则调整首次执行当年年初财务报表相关情况

(III) Description of adjustments in opening balances of line items in financial statements of the year due to the implementation of new lease standard since 2021

√适用 □不适用

√ Applicable □ Not Applicable

合并资产负债表

Consolidated Balance Sheet

2021年1-9月

For the period from January 1, 2021 to September 30, 2021

编制单位:甘李药业股份有限公司

Prepared by: Gan & Lee Pharmaceuticals.

单位:元 币种:人民币 审计类型:未经审计
In RMB, Unaudited

项目	Item	2020年12月31日 December 31, 2020	2021年1月1日 January 1, 2021	调整数 Adjusted amount
流动资产:	Current Assets:			
货币资金	Cash and Cash equivalents	2,824,811,610.48	2,824,811,610.48	
交易性金融资产	Held-for-trading financial assets	787,050,475.77	787,050,475.77	
应收账款	Accounts receivable	827,076,539.93	827,076,539.93	
应收款项融资	Financing receivables	268,760.00	268,760.00	
预付款项	Prepayments	70,242,083.92	70,242,083.92	
其他应收款	Other receivables	5,001,469.72	5,001,469.72	
存货	Inventories	493,481,641.77	493,481,641.77	
一年内到期的非流动资产	Current portion of non-current assets	108,341,438.36	108,341,438.36	
其他流动资产	Other current assets	843,339,501.94	843,339,501.94	
流动资产合计	Total current Assets	5,959,613,521.89	5,959,613,521.89	
非流动资产:	Non-current Assets:			
债权投资	Debt investments	466,047,945.21	466,047,945.21	
固定资产	Fixed assets	1,738,877,768.05	1,738,877,768.05	
在建工程	Construction in progress	410,124,488.85	410,124,488.85	
使用权资产	Use right assets		15,622,797.91	15,622,797.91
无形资产	Intangible assets	238,917,726.54	238,917,726.54	
开发支出	Development expenditures	530,704,797.92	530,704,797.92	
长期待摊费用	Long-term prepaid expenses	13,570,027.42	13,570,027.42	
递延所得税资产	Deferred tax assets	14,927,523.58	14,927,523.58	
其他非流动资产	Other non-current assets	134,665,046.69	134,665,046.69	
非流动资产合计	Total non-current Assets	3,547,835,324.26	3,563,458,122.17	15,622,797.91
资产总计	Total assets	9,507,448,846.15	9,523,071,644.06	15,622,797.91

合并资产负债表 (续)

Consolidated Balance Sheet (Continued)

项目	Item	2020年12月31日 December 31, 2020	2021年1月1日 January 1, 2021	调整数 Adjusted amount
流动负债：	Current Liabilities			
应付账款	Accounts payable	17,813,897.58	17,813,897.58	
合同负债	Contract liabilities	68,442,734.65	68,442,734.65	
应付职工薪酬	Payroll and employee benefits payable	105,502,987.37	105,502,987.37	
应交税费	Taxes payable	66,741,390.93	66,741,390.93	
其他应付款	Other payables	141,312,224.65	141,312,224.65	
一年内到期的非流动负债	Current portion of non-current liabilities	9,087,839.22	9,087,839.22	
其他流动负债	Other current liabilities	949,097.54	949,097.54	
流动负债合计	Total Current Liabilities	409,850,171.94	409,850,171.94	
非流动负债：	Non-current Liabilities:			
租赁负债	Leasing liabilities		15,622,797.91	15,622,797.91
长期应付款	Long-term payable	1,690,159.92	1,690,159.92	
递延收益	Deferred income	125,769,330.10	125,769,330.10	
递延所得税负债	Deferred tax liabilities	31,781,078.01	31,781,078.01	
非流动负债合计	Total Non-current Liabilities	159,240,568.03	174,863,365.94	15,622,797.91
负债合计	Total Liabilities	569,090,739.97	584,713,537.88	15,622,797.91
所有者权益(或股东权益)：	Owners' (or Shareholders') Equity:			
实收资本(或股本)	Paid-in capital (or share capital)	561,540,000.00	561,540,000.00	
资本公积	Capital reserve	2,473,623,419.43	2,473,623,419.43	
其他综合收益	Other comprehensive income	-1,550,987.58	-1,550,987.58	
盈余公积	Surplus reserve	291,531,843.96	291,531,843.96	
未分配利润	Retained earnings	5,613,376,105.59	5,613,376,105.59	
归属于母公司所有者权益(或股东权益)合计	Equity attributable to owners of the parent	8,938,520,381.40	8,938,520,381.40	
少数股东权益	Non-controlling interests	-162,275.22	-162,275.22	
所有者权益(或股东权益)合计	Total Owners' (or Shareholders') Equity	8,938,358,106.18	8,938,358,106.18	
负债和所有者权益(或股东权益)总计	Total Liabilities and Owners'(or Shareholders') Equity	9,507,448,846.15	9,523,071,644.06	15,622,797.91

各项目调整情况的说明：

Description of adjustments on each item:

√适用 □不适用

√ Applicable □ Not Applicable

本公司自 2021 年 1 月 1 日起执行新租赁准则，根据首次执行新租赁准则的影响数，调整首次执行当年年初财务报表相关项目金额。

The company will implement the new lease standard on January 1, 2021, and adjust the amount of relevant items in the financial statements at the beginning of the year when the new lease standard is first implemented based on the impact of the first implementation of the new lease standard.

特此公告。


Special announcement.

甘李药业股份有限公司董事会

Gan & Lee Pharmaceuticals. Board of Directors

2021年10月26日

October 26, 2021



Gan & Lee

甘李药业股份有限公司

Gan&Lee Pharmaceuticals.

地址：北京市通州区潮县镇南凤西一路8号

网址：www.ganlee.com

电话：+86 010-80593699

邮编：101109